HEPA
Hepion Pharmaceuticals, Inc.
$0.0610
-23.75%
No data for this timeframe.
Vol
Inst. Holders5 funds
Inst. Value$6.8K
Inst. Activity0 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$350.0K
SEC Reports2
Recent Activity
Apr 27, 2026
SEC
Four Hepion insiders, including the Interim CEO and Executive Chairman, purchased $350K in shares at $0.04 on April 21,
CLUSTER — Impact 5/10
Apr 27, 2026
SEC
Two corporate insiders at Hepion Pharmaceuticals, including the Interim CEO, purchased $100,000 worth of shares in open-
CLUSTER — Impact 6/10
Apr 21, 2026
Insider
Stetz Gary S. bought 1,250,000 shares
Interim CEO @ $0.0400 ($50.0K)
Apr 21, 2026
Insider
Appajosyula Sireesh bought 1,250,000 shares
Director @ $0.0400 ($50.0K)
Apr 21, 2026
Insider
LoPriore Vincent S bought 5,000,000 shares
Executive Chairman @ $0.0400 ($200.0K)
Inst.
VANGUARD GROUP INC — EXIT
0 shares ($0.00)
Inst.
UBS Group AG — DOUBLED
14,032 shares ($6.6K)
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Dec 7, 2023 | Brookline Capital | DOWNGRADE | Buy → Hold |
Latest Reports
MIXED
CLUSTER
5/10
Four Hepion insiders, including the Interim CEO and Executive Chairman, purchased $350K in shares at $0.04 on April 21,
Apr 27, 2026
MIXED
CLUSTER
6/10
Two corporate insiders at Hepion Pharmaceuticals, including the Interim CEO, purchased $100,000 worth of shares in open-
Apr 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BANK OF AMERICA CORP | — | — |
| UBS Group AG | — | DOUBLED |
| CITADEL ADVISORS LLC | $6.7K | EXIT |
| FMR LLC | $43.00 | — |
| MORGAN STANLEY | $13.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 21, 2026 | Stetz Gary | BUY | $50.0K |
| Apr 21, 2026 | Appajosyula Sireesh | BUY | $50.0K |
| Apr 21, 2026 | LoPriore Vincent | BUY | $200.0K |
| Apr 21, 2026 | Purcell Michael | BUY | $50.0K |
5 institutional holders with $6.8K total value (15,714 shares) as of 2025-Q1. Top holders: BANK, UBS, CITADEL. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | 2 | $0.00 | 0.0% | — |
| 2 | UBS Group AG | 1 | $0.00 | 0.0% | DOUBLED +467633.3% |
| 3 | CITADEL ADVISORS LLC | 15,581 | $6.7K | 99.2% | EXIT -100.0% |
| 4 | FMR LLC | 100 | $43.00 | 0.6% | — |
| 5 | MORGAN STANLEY | 30 | $13.00 | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | EXIT | 50,251 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 3 | 14,032 | +467633.3% | $6.6K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 29,307 | 0 | -100.0% | $0.00 | 2024-Q4 |
4 unique insiders with 4 transactions. Net insider value: $350.0K ($350.0K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 21, 2026 | Stetz Gary S. | Interim CEO | BUY | 1,250,000 | $0.0400 | $50.0K |
| Apr 21, 2026 | Appajosyula Sireesh | Director | BUY | 1,250,000 | $0.0400 | $50.0K |
| Apr 21, 2026 | LoPriore Vincent S | Executive Chairman | BUY | 5,000,000 | $0.0400 | $200.0K |
| Apr 21, 2026 | Purcell Michael J. | Director | BUY | 1,250,000 | $0.0400 | $50.0K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 2 mixed, 0 neutral. Avg impact: 5.5/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Dec 2023): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2024-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2024-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Dec 7, 2023 | Brookline Capital | DOWNGRADE | Buy | Hold |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Dec 1, 2024 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.